Review article: investigational agents for chronic hepatitis C
AJV Thompson, JG Mchutchison
Alimentary Pharmacology & Therapeutics | WILEY | Published : 2009
BACKGROUND: The need for effective treatment for chronic hepatitis C infection has driven the development of novel antiviral agents that target specific steps in the viral replication cycle. AIM: To evaluate the current literature concerning investigational agents for chronic hepatitis C virus infection. METHODS: Resources used included PubMed, conference proceedings from the American and European Liver Associations' meetings 2005-2008 and the National Institute of Health's clinical trials website (http://www.clinicaltrials.gov). The focus was restricted to investigational agents that have progressed beyond preclinical development. RESULTS: Over 50 investigational agents for chronic hepatiti..View full abstract
Declaration of personal interests: (i) Alex Thompson has served as a speaker and an advisory board member for Roche Pharmaceuticals. (ii) John McHutchison has received in the past or currently receives grant/research support from Anadys Pharmaceuticals, Inc., GlaxoSmithKline, Globeimmune, Human Genome Sciences, Idenix, Intarcia, National Institutes of Health (NIH), Novartis Pharmaceuticals, Inc., Pfizer Pharmaceuticals, Inc., Pharmasset Inc., Roche Pharmaceuticals, Schering-Plough Corporation, Vertex Pharmaceuticals, Wyeth. Dr McHutchison has been or is currently a consultant/advisor for: Anadys Pharmaceuticals, Inc., Biolex, Biocryst, Epiphany, GlaxoSmithKline, Human Genome Sciences, Idera, Intarcia, ItheRx, National Genetics Institute, Novartis Pharmaceuticals, Inc., Peregrine, Pfizer Pharmaceuticals, Inc., Pharmasset, Inc., Sanofi-Aventis, Schering-Plough Corporation, Vertex Pharmaceuticals, Wyeth, XTL. Declaration of funding interests: None.